Alnylam Pharmaceuticals Valuation
Is A1LN34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A1LN34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A1LN34 (R$74.14) is trading below our estimate of fair value (R$109.86)
Significantly Below Fair Value: A1LN34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A1LN34?
Key metric: As A1LN34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is A1LN34's PS Ratio? | |
|---|---|
| PS Ratio | 15.6x |
| Sales | US$2.09b |
| Market Cap | US$32.68b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 15.6x |
| Enterprise Value/EBITDA | -246.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A1LN34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.1x | ||
BLAU3 Blau Farmacêutica | 1.5x | 11.6% | R$2.7b |
BIOM3 Biomm | 8.9x | n/a | R$1.1b |
HZNP Horizon Therapeutics | 7.3x | 8.3% | US$26.6b |
NTRA Natera | 14.5x | 12.3% | US$22.2b |
A1LN34 Alnylam Pharmaceuticals | 15.6x | 22.4% | R$32.7b |
Price-To-Sales vs Peers: A1LN34 is expensive based on its Price-To-Sales Ratio (15.6x) compared to the peer average (8.3x).
Price to Sales Ratio vs Industry
How does A1LN34's PS Ratio compare vs other companies in the Global Biotechs Industry?
| 274 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 274 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: A1LN34 is expensive based on its Price-To-Sales Ratio (15.6x) compared to the Global Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is A1LN34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 15.6x |
| Fair PS Ratio | 10x |
Price-To-Sales vs Fair Ratio: A1LN34 is expensive based on its Price-To-Sales Ratio (15.6x) compared to the estimated Fair Price-To-Sales Ratio (10x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Gilead Sciences
US$113.8b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD34
US$272.97
7D
7.6%
1Y
48.5%
Novartis
CHF 185.4b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.77
7D
2.7%
1Y
28.3%
BeiGene
US$20.4b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
B1GN34
US$49.40
7D
8.9%
1Y
n/a